# Study to Develop a Screening Tool for Functional Capacity in Anemic Subjects With Nonmyeloid Malignancies Receiving Chemotherapy and Darbepoetin Alfa

> **NCT00540696** · PHASE2 · COMPLETED · sponsor: **Amgen** · enrollment: 300 (estimated)

## Conditions studied

- Anemia
- Non-Myeloid Malignancies

## Interventions

- **DRUG:** darbepoetin alfa

## Key facts

- **NCT ID:** NCT00540696
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2001-09
- **Primary completion:** 2003-06
- **Final completion:** 2003-09
- **Target enrollment:** 300 (ESTIMATED)
- **Last updated:** 2013-04-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00540696

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00540696, "Study to Develop a Screening Tool for Functional Capacity in Anemic Subjects With Nonmyeloid Malignancies Receiving Chemotherapy and Darbepoetin Alfa". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00540696. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*